Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

nucare pharmaceuticals,inc. - sumatriptan succinate (unii: j8bdz68989) (sumatriptan - unii:8r78f6l9vo) - sumatriptan 50 mg - sumatriptan tablets, usp are indicated for the acute treatment of migraine with or without aura in adults. limitations of use: - use only if a clear diagnosis of migraine headache has been established. if a patient has no response to the first migraine attack treated with sumatriptan tablets, usp, reconsider the diagnosis of migraine before sumatriptan tablets, usp are administered to treat any subsequent attacks. - sumatriptan tablets, usp are not indicated for the prevention of migraine attacks. - safety and effectiveness of sumatriptan tablets, usp have not been established for cluster headache. sumatriptan tablets are contraindicated in patients with:  - ischemic coronary artery disease (cad) (angina pectoris, history of myocardial infarction, or documented silent ischemia) or coronary artery vasospasm, including prinzmetal’s angina [see warnings and precautions (5.1)] - wolff-parkinson-white syndrome or arrhythmias associated with other cardiac accesso

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

proficient rx lp - sumatriptan succinate (unii: j8bdz68989) (sumatriptan - unii:8r78f6l9vo) - sumatriptan 50 mg - sumatriptan tablets, usp are indicated for the acute treatment of migraine with or without aura in adults. limitations of use: sumatriptan tablets are contraindicated in patients with:  teratogenic effects pregnancy category c: there are no adequate and well-controlled trials in pregnant women. in developmental toxicity studies in rats and rabbits, oral administration of sumatriptan to pregnant animals was associated with embryolethality, fetal abnormalities, and pup mortality. when administered by the intravenous route to pregnant rabbits, sumatriptan was embryolethal. sumatriptan tablets should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. oral administration of sumatriptan to pregnant rats during the period of organogenesis resulted in an increased incidence of fetal blood vessel (cervicothoracic and umbilical) abnormalities. the highest no-effect dose for embryofetal developmental toxicity in rats was 60 mg/kg/day, or approximately 3 times

Βέλγιο - Ολλανδικά - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

teva pharma belgium sa-nv - sumatriptansuccinaat 140 mg - eq. sumatriptan 100 mg - filmomhulde tablet - 100 mg - sumatriptansuccinaat 140 mg - sumatriptan

Βέλγιο - Ολλανδικά - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

teva pharma belgium sa-nv - sumatriptansuccinaat 70 mg - eq. sumatriptan 100 mg - filmomhulde tablet - 50 mg - sumatriptansuccinaat 70 mg - sumatriptan

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

dr. reddy's laboratories limited - sumatriptan succinate (unii: j8bdz68989) (sumatriptan - unii:8r78f6l9vo) - sumatriptan 25 mg - sumatriptan tablets are indicated for the acute treatment of migraine with or without aura in adults.   limitations of use: • use only if a clear diagnosis of migraine headache has been established. if a patient has no response to the first migraine attack treated with sumatriptan, reconsider the diagnosis of migraine before sumatriptan tablets are administered to treat any subsequent attacks. • sumatriptan tablets are not indicated for the prevention of migraine attacks. • safety and effectiveness of sumatriptan tablets have not been established for cluster headache. sumatriptan tablets are contraindicated in patients with: • ischemic coronary artery disease (cad) (angina pectoris, history of myocardial infarction, or documented silent ischemia) or coronary artery vasospasm, including prinzmetal’s angina [see warnings and precautions (5.1 )] • wolff-parkinson-white syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders [see warnings and precautions (5.2 )]  • history of

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

fresenius kabi usa, llc - sumatriptan succinate (unii: j8bdz68989) (sumatriptan - unii:8r78f6l9vo) - sumatriptan 6 mg in 0.5 ml - sumatriptan injection is indicated in adults for (1) the acute treatment of migraine, with or without aura, and (2) the acute treatment of cluster headache. limitations of use: - use only if a clear diagnosis of migraine or cluster headache has been established. if a patient has no response to the first migraine or cluster headache attack treated with sumatriptan injection, reconsider the diagnosis before sumatriptan injection is administered to treat any subsequent attacks. - sumatriptan injection is not indicated for the prevention of migraine or cluster headache attacks. sumatriptan injection is contraindicated in patients with: - ischemic coronary artery disease (cad) (angina pectoris, history of myocardial infarction, or documented silent ischemia) or coronary artery vasospasm, including prinzmetal's angina [see warnings and precautions (5.1)] . - wolff-parkinson-white syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders [see warnings and precautions (5.2)] . - hi

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

lake erie medical dba quality care products llc - sumatriptan succinate (unii: j8bdz68989) (sumatriptan - unii:8r78f6l9vo) - sumatriptan 25 mg - sumatriptan succinate tablets are indicated for the acute treatment of migraine attacks with or without aura in adults.  sumatriptan succinate tablets are not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine (see contraindications). safety and effectiveness of sumatriptan succinate tablets have not been established for cluster headache, which is present in an older, predominantly male population. sumatriptan succinate tablets should not be given to patients with history, symptoms, or signs of ischemic cardiac, cerebrovascular, or peripheral vascular syndromes. in addition, patients with other significant underlying cardiovascular diseases should not receive sumatriptan succinate tablets. ischemic cardiac syndromes include, but are not limited to, angina pectoris of any type (e.g., stable angina of effort and vasospastic forms of angina such as the prinzmetal variant), all forms of myocardial infarction, and silent myocardial ischemia. cerebrovasc

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - sumatriptan succinate, quantity: 139.98 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; hypromellose; microcrystalline cellulose; lactose monohydrate; magnesium stearate; titanium dioxide - sumatrip tablets are indicated for the acute relief of migraine attacks with or without aura.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - sumatriptan succinate, quantity: 69.99 mg - tablet, film coated - excipient ingredients: magnesium stearate; lactose monohydrate; hypromellose; microcrystalline cellulose; croscarmellose sodium; titanium dioxide; triacetin; iron oxide red - sumatrip tablets are indicated for the acute relief of migraine attacks with or without aura.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - sumatriptan succinate, quantity: 140 mg (equivalent: sumatriptan, qty 100 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; croscarmellose sodium; lactose monohydrate; magnesium stearate; titanium dioxide; hypromellose; macrogol 8000; triacetin; polydextrose - iptam tablets are indicated for the acute relief of migraine attacks with or without aura. there is no information available on the use of iptam in the treatment of basilar or hemiplegic migraines.